BIR
BIR Financial Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
BIR Financial Ltd. engages in the provision of financial services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2006-07-31. The firm operates through its wholly owned subsidiary Pulse Markets Pty Ltd (Pulse Markets). The company is engaged in one business and geographical segment, namely equity capital markets trading. The principal activity of the Company is the development of Pulse Markets's equity capital markets and brokerage activities. Pulse Markets is a diversified financial services business, which provides a range of financial services to retail, institutional, corporate and private clients. These services include transacting equities and derivatives on the Australian Securities Exchange (ASX) and raising equity capital. Pulse Markets operates a wholly owned subsidiary Selecta Funds Management Pty Ltd.
📈 Performance
Price History
-64.33%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.06
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BIR
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in BIR
N/A
BIR investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in BIR also invest in...
Want more shares? Try these...
Bisalloy Steel Group Ltd. engages in the production and sale of bisalloy quenched and tempered steel plate. The company is headquartered in Wollongong, New South Wales. The company went IPO on 2003-06-23. The firm operates through two geographic segments: Australia and Overseas. The Australian operations are comprised of Bisalloy Steels Pty Limited and Bisalloy Steel Group Limited. Bisalloy Steels Pty Limited manufactures and sells wear-grade and high tensile plate through distributors and directly to original equipment manufacturers in both Australia and Overseas. The Overseas operations comprise PT Bima Bisalloy and Bisalloy (Thailand) Co Limited located in Indonesia and Thailand respectively. These businesses distribute Bisalloy Q&T plate as well as other steel plate products. The Overseas operations also include the co-operative joint venture Bisalloy Shangang (Shandong) Steel Plate Co. Limited, which is engaged in marketing, sale and distribution of quench and tempered steel plate.
📊 Share price
$1.93 AUD
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The firm is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. The company also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.
📊 Share price
$0.03 AUD
Bindi Metals Ltd. engages in the acquisition, exploration and development of mineral exploration assets. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-06-28. The firm's projects include The Biloela Project, Flanagan's Project and Great Blackall Project. The Biloela Project comprises one granted Exploration Permit for Minerals (EPM) 27428, which covers a total area of 20 sub-blocks for an area of approximately 62 square kilometers (km). The Biloela Project is located approximately 30 km southeast of Biloela, 93 km southwest of the Port of Gladstone and 390 km north-northwest of Brisbane. The prospects on the Biloela Tenement are: Flanagans, Great Blackall, Inverted Pig Prospect, and Quartz Ridge. Its Flanagan's Project is 1.5 kilometer long by 180-meter wide outcropping gold rich mineralized zone hosted by diorite. The firm's Great Blackall Project covers over 500 meter of outcropping high-grade copper - gold mineralization with numerous historical shafts. The Inverted Pig prospect occurs immediately south of the Great Blackall Copper prospect.
📊 Share price
$0.19 AUD
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The company develops, licenses, commercializes and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products are marketed under three brands: Activated Probiotics, Activated Nutrients and Activated X Performance. Its products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The firm distributes its products in Australia, New Zealand and the United Kingdom. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trails.
📊 Share price